CytomX Therapeutics (NASDAQ:CTMX) Upgraded at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from a neutral rating to an overweight rating in a research note released on Monday morning, Marketbeat reports. They currently have $12.00 target price on the biotechnology company’s stock, up from their previous target price of $7.00.

Several other research analysts also recently commented on the stock. Piper Sandler lifted their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Cantor Fitzgerald upped their price objective on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. Barclays increased their target price on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Finally, Guggenheim reiterated a “buy” rating and issued a $10.00 target price on shares of CytomX Therapeutics in a research report on Monday, March 9th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, CytomX Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $12.56.

CytomX Therapeutics Trading Down 19.3%

Shares of CytomX Therapeutics stock opened at $4.40 on Monday. The firm has a market capitalization of $748.84 million, a PE ratio of -110.00 and a beta of 2.44. The business’s 50-day moving average price is $5.27 and its 200-day moving average price is $4.10. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million. CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%. As a group, analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Trading of CytomX Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CTMX. Wells Fargo & Company MN boosted its stake in shares of CytomX Therapeutics by 83.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,000 shares during the period. Farther Finance Advisors LLC purchased a new position in shares of CytomX Therapeutics in the third quarter worth $25,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of CytomX Therapeutics in the fourth quarter worth $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in CytomX Therapeutics during the 3rd quarter valued at $34,000. Finally, May Hill Capital LLC bought a new stake in CytomX Therapeutics during the 4th quarter valued at $46,000. Institutional investors own 67.77% of the company’s stock.

Trending Headlines about CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple analysts raised price targets or upgraded the stock — Guggenheim raised its target to $15 and put a Buy on CTMX, Wedbush raised its target to $11 with an Outperform, and JPMorgan issued an upgrade — these notes signal continued institutional interest and provide upside conviction for the shares. Benzinga JPMorgan Upgrade
• Positive Sentiment: Clinical catalyst: strong Phase I Varseta‑M data in metastatic colorectal cancer previously triggered a rally and underpins investor optimism about the pipeline’s upside. Zacks
• Neutral Sentiment: Company posted its Q4 results presentation (useful for diligence), providing the latest formal disclosures on operations and pipeline progress. Investors should review the deck for cash runway details and program timelines. Q4 Presentation
• Negative Sentiment: Dilutive equity financing: CytomX priced a $250M offering at $5.30/share (≈46M shares plus pre‑funded warrants). The sale increases share count materially and is the primary near‑term headwind pressuring the stock. Offering Filing
• Negative Sentiment: HC Wainwright lowered near‑term EPS forecasts substantially (Q1–Q4 2026 and FY2026 cuts) even while maintaining a Buy and a $17 target; the reduced estimates highlight expected near‑term cash burn and push downside to short‑term earnings expectations. Analyst Note
• Negative Sentiment: Recent quarter missed consensus on EPS and revenue (reported March 16), underscoring why the company sought additional capital and why near‑term profitability looks distant. Earnings Coverage

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.